Page 56 - Priority Review News Today

The FDA has granted priority review to the biologics license application for the tumor infiltrating lymphocyte therapy lifileucel for the treatment of patients with advanced melanoma who progressed on or after prior anti–PD-1/PD-L1 therapy and targeted therapy.

26.05.2023 - Priority Review Granted withPrescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 First Potential Approval of an Individualized, One-Time Cell Therapy for Patients with Advanced Melanoma SAN CARLOS, Calif., May 26, 2023 ... Seite 1

The FDA has granted priority review to the new drug application seeking the approval of fruquintinib for use in the treatment of adult patients with previously treated metastatic colorectal cancer.

- Nirogacestat Treatment Demonstrated Rapid, Sustained and Consistent Reductions in Pain Compared to Placebo Using Multiple Assessment Tools - - Substantial Reductions in MRI-Assessed Tumor Volume... | May 25, 2023

Results from Phase 3 COMMANDS study, selected for ASCO’s official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with... | May 25, 2023

Results from Phase 3 COMMANDS study, selected for ASCO's official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with concurrent

US FDA approves new treatment for pneumonia caused by certain difficult-to-treat bacteria

Business Scoop provides news and views on Business and Markets from New Zealand

TOKYO, May 20, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) for lecanemab, an investigational anti-amyloid beta (A) protofibril antibody, for the treatment ...

TOKYO, May 20, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) for lecanemab, an investigational anti-amyloid